| Course | NR 546 Advanced Pharmacology: Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner |
|---|---|
| Week | 4 |
| Paper type | Titration and monitoring plan |
| Length | About 1,140 words, 2 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | MSN, Psychiatric-Mental Health Nurse Practitioner (PMHNP) |
| Updated | September 2026 |
Free sample paper for NR 546 Week 4
Titration and Monitoring Plan: Escitalopram From 5 mg to a Possible 20 mg Over Twelve Weeks, With Baseline Checks, Dated Review Points, Actions Attached to Results and a Rule for Stopping
Student Name
College of Nursing, Chamberlain University
NR 546: Advanced Pharmacology: Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner
Instructor Name
Month Day, Year
Titration and Monitoring Plan: Escitalopram From 5 mg to a Possible 20 mg Over Twelve Weeks, With Baseline Checks, Dated Review Points, Actions Attached to Results and a Rule for Stopping
Purpose
This plan sets out how escitalopram will be started, increased and monitored for the teacher described in the selection rationale, whose first depressive episode carries the anxious distress specifier. It is written so that a colleague covering a visit could follow it without asking what was intended. Each step carries a reason, a time and the result that would prompt an action.
The plan also records what the patient agreed to. The patient knows the dose will rise at day 8, understands that a further increase depends on the week 6 score and has agreed to the two-week call. A plan the patient has not agreed to is unlikely to be followed, and writing down the agreement lets a covering clinician see what was promised.
Baseline Before the First Dose
Each baseline item is taken for a reason connected to this drug or this patient.
Rating scales. PHQ-9 (baseline 18) and GAD-7 (baseline 13), so later scores can be compared with a fixed starting point rather than with memory.
Suicide risk. Columbia Suicide Severity Rating Scale screen, which found passive death wishes without plan or intent. A written safety plan was completed with the patient, including crisis line numbers and the name of a support person, because risk must be followed from a known baseline and because the early weeks of treatment need a plan in place.
Bipolar screening. A structured screening questionnaire and history for any past stretch of days with unusually high mood or little need for sleep, plus family history. All negative. Screening is done because an antidepressant alone can trigger mania in unrecognized bipolar disorder.
Sexual function and weight. A brief question about current sexual function and a recorded weight (91 kg). Sexual dysfunction and weight change are common reasons patients stop antidepressants, and neither can be judged later without a baseline.
Medication and substance review. Sumatriptan about twice monthly, ibuprofen occasionally, alcohol about two glasses of wine most evenings. The triptan and the anti-inflammatory both interact with serotonergic antidepressants, and alcohol worsens both sleep and mood.
Pregnancy status. Not pregnant; intrauterine device in place.
Laboratory tests. No routine laboratory tests are required before escitalopram in a healthy 41-year-old. Thyroid-stimulating hormone was checked because thyroid disease can present with low mood and fatigue; it was normal. An electrocardiogram is not needed at this age with no cardiac history and no other QT-prolonging drugs.
Starting Dose and Steps
Days 1 to 7: escitalopram 5 mg each morning. Started below the usual 10 mg because of the patient's earlier activation on fluoxetine and diarrhea-predominant irritable bowel syndrome.
Day 8 onward: 10 mg each morning. Increase if the first week was tolerated. If nausea or loose stools are still troublesome, stay at 5 mg for a second week before increasing.
Week 6: consider 20 mg. Increase to 20 mg if the PHQ-9 has improved by less than 50% from baseline, the patient has taken 10 mg consistently for at least four weeks, and side effects are tolerable. The wait is set at four weeks at 10 mg because benefit continues to accumulate over several weeks (Taylor et al., 2006), and increasing too early would expose the patient to more side effects before the lower dose has had a fair trial.
Ceiling: 20 mg daily. This is the maximum recommended adult dose. Higher doses add risk, including dose-related QT prolongation, without clear benefit (Stahl, 2021).
Monitoring on the Schedule
Week 1 or 2, phone or video contact by the prescriber. Tolerability, especially nausea, diarrhea, restlessness and sleep. Suicidal thinking reviewed using the same screening questions. Any agitation or signs of elevated mood.
Week 4, visit. PHQ-9, GAD-7 and the suicide screen. Weight. Direct question about sexual function. Adherence, asked as how many doses were missed in the past week. Alcohol use.
Week 6, visit. PHQ-9 and GAD-7 to decide on the dose increase. Side effects.
Week 8 and week 12, visits. PHQ-9, GAD-7, weight, sexual function, adherence and the suicide screen. At week 12 the plan is reviewed as a whole.
The prescriber is responsible for each contact; the clinic's nurse schedules them before the patient leaves the first visit.
If the patient misses a scheduled contact, the nurse calls the same day to rebook it, since a missed early contact is itself a warning sign.
Actions Attached to Results
Table 1 sets out the result at each point and the action it would prompt.
Monitoring results and the actions they trigger
Table 1
| Finding | Action |
|---|---|
| Nausea or loose stools in week 1 | Take with food; stay at 5 mg for a further week |
| PHQ-9 improved 50% or more at week 6 | Continue 10 mg; review at week 8 |
| PHQ-9 improved less than 50% at week 6, adherent, tolerating | Increase to 20 mg; review in 2 to 4 weeks |
| Less than 20% improvement at week 8 despite adherence and adequate dose | Review diagnosis, substances and medical causes; consider switch or augmentation |
| New sexual dysfunction the patient finds unacceptable | Discuss options, including adding or switching to bupropion |
| Missed doses more than twice a week | Explore reasons before any dose change |
| Weight gain of more than 5% from baseline | Review diet and activity; reconsider agent |
Stopping Rules
The plan stops, and the patient is reassessed the same day, if any of the following occur: suicidal thinking with intent or a plan; symptoms of hypomania or mania, such as reduced need for sleep with increased energy, racing thoughts or unusual risk-taking; symptoms suggesting serotonin toxicity, such as agitation, tremor, sweating, fever and muscle twitching, particularly after taking sumatriptan; or unusual bleeding, since serotonergic antidepressants affect platelet function and the patient takes ibuprofen at times (Carvalho et al., 2016). In each case escitalopram is held and the patient is seen urgently or directed to emergency care, depending on severity.
If the plan ends because of an intolerable but non-dangerous side effect, escitalopram will be reduced gradually across a week or two instead of stopped at once, to reduce discontinuation symptoms such as dizziness, irritability and flu-like feelings.
Duration
If the patient responds, treatment will continue at the effective dose for a minimum of six to nine months beyond remission, because stopping early raises the risk of relapse. The plan will be reviewed at that point with the patient, and any discontinuation will be gradual.
References
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016). The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: A critical review of the literature. Psychotherapy and Psychosomatics, 85(5), 270-288. https://doi.org/10.1159/000447034
Stahl, S. M. (2021). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (5th ed.). Cambridge University Press.
Taylor, M. J., Freemantle, N., Geddes, J. R., & Bhagwagar, Z. (2006). Early onset of selective serotonin reuptake inhibitor antidepressant action: Systematic review and meta-analysis. Archives of General Psychiatry, 63(11), 1217-1223. https://doi.org/10.1001/archpsyc.63.11.1217
The Chamberlain NR 546 Week 4 instructions
This week asks you to design a titration and monitoring plan for a psychotropic medication. The instructions will likely request baseline assessments, starting dose, titration schedule, monitoring parameters with timing, actions based on results and criteria for stopping. List baseline items and give a reason each is needed for this drug and patient. State the starting dose and why. Set each increase with its interval and the finding that would justify it, rather than a target dose to reach as tolerated. Place monitoring on specific dates with named tests or scales. Attach an action to each possible result. Include a stopping rule naming the findings that would halt treatment, and say how the drug would be tapered. Say who is responsible for each step. Cite prescribing references in APA 7.
Inside the NR 546 Week 4 example
The plan opens with its purpose and records what the patient agreed to. The baseline section lists PHQ-9 and GAD-7, a suicide screen with a written safety plan, bipolar screening, sexual function and weight, medication and alcohol review, pregnancy status and a thyroid test, noting that an electrocardiogram is not needed at this age. The steps section sets 5 mg for a week, then 10 mg, and a possible 20 mg at week 6 after four weeks at 10 mg, with a 20 mg ceiling. Monitoring is scheduled at weeks 1 to 2, 4, 6, 8 and 12. Table 1 attaches actions to results. Stopping rules name four urgent findings. A final section sets the duration after remission and the taper.
Reading the NR 546 Week 4 grading rubric
Titration plans are typically weighed on completeness and justification of baseline assessments, a safe starting dose, a clear titration schedule, specific monitoring, actions linked to results and appropriate stopping criteria. A plan that reads like a timetable, with dates, tests and responsibilities, earns more than a narrative. Giving a reason for every baseline item shows understanding rather than routine. Each dose increase tied to an interval and a finding shows careful prescribing. A table linking results to actions makes the plan usable by another clinician. A stopping rule, with urgent reassessment and a taper, marks a complete plan. Attention to the patient's agreement and to safety screening strengthens the plan, and APA 7 citations to prescribing sources support it.
NR 546 Week 4 help: mistakes that cost points
Plans often say to start low and titrate as tolerated, which gives a covering clinician nothing to follow. Name doses, intervals and triggers. Another weakness is monitoring described as ongoing without saying what is checked or when. Put each check on the schedule. Some students list baseline tests without explaining why this drug needs them, or order tests that are not indicated. Justify each. Omitting a stopping rule is a common and costly gap. Say what would halt treatment and what happens next. Avoid increasing the dose before the lower dose has had a fair trial. Include the taper, since abrupt stopping causes discontinuation symptoms. Make sure responsibilities are clear, so every contact on the schedule actually happens.
Get a NR 546 Week 4 example written to your instructions
Send the Week 4 instructions along with the agent and the patient your section supplies, and a custom example is built as a schedule and returned inside 24 to 48 hours. The first one is free. Any monitoring ordered at your own site remains your responsibility.
More NR 546 papers and PMHNP samples
- NR 546 Week 1: Antidepressant Timing Discussion
- NR 546 Week 2: Receptor Mechanism Write-Up
- NR 546 Week 3: Medication Selection Rationale
- NR 546 Week 5: Case Analysis
- NR 546 Week 6: Adverse Effect Brief
- NR 546 Week 7: Medication Education Handout
- NR 546 Week 8: Psychopharmacology Case Paper
NR 546 Week 4 questions, answered
How specific do the monitoring intervals have to be?
Specific enough to be put in a diary. Named tests with weeks attached read as a plan; regular monitoring reads as a phrase. Where the interval depends on a result, say so and give both branches, because a grader is checking whether a colleague could pick the plan up and know what to do next without asking you.
What if the reference gives a range rather than a starting dose?
Choose inside the range and justify the choice from the patient. Age, renal or hepatic function, comorbidity, prior sensitivity and interacting medications are the usual reasons to start low. A plan that names the range and then picks the midpoint without comment is the version that reads as copied rather than decided.
Should the plan cover what happens if it works?
Yes, and most drafts forget. A stopping rule for adverse effects is one half; the other is what happens at the point of response, whether the dose holds, how long it continues, and when the question of duration gets raised. Sections differ on how far ahead they expect you to plan, so check the instructions.
Where can I find a free NR 546 Week 4 sample paper?
The escitalopram titration and monitoring plan appears above as the NR 546 Week 4 sample, readable without an account. If you are planning a different medication, share the drug and the patient and a plan with dates, actions and a stopping rule can be written.
What does a stopping rule look like in NR 546 Week 4?
A list of findings that would halt treatment the same day, with what happens next. The sample stops for suicidal intent, signs of mania, serotonin toxicity or unusual bleeding.